Literature DB >> 15865067

Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin.

Eve Maubec1, Pierre Duvillard, Valérie Velasco, Béatrice Crickx, Marie-Françoise Avril.   

Abstract

BACKGROUND: Metastatic squamous cell carcinoma (SCC) of the skin often raise difficult therapeutic problems. Few data are available about the expression of EGFR and HER-2 in SCC of the skin. Overexpression of EGFR and of HER-2 proteins has been reported. The purpose of this study was to investigate the expression of EGFR and HER-2 in a series of metastatic SCC of the skin. PATIENTS AND METHODS: EGFR and HER-2 expression was studied by immunochemistry on 13 specimens of metastatic recurrence and on 2 primary lesions of these tumours.
RESULTS: EGFR had a strong membranous expression in all specimens. HER-2 was weakly expressed in 4 specimens, with a membrane expression in 2 cases.
CONCLUSION: In the present study, EGFR was overexpressed in all samples of metastatic SCCs of the skin. Therefore, these metastatic tumours appear to be suitable targets for treatment with tyrosine kinase inhibitors. Additional studies are warranted to establish whether or not HER-2 is expressed in SCC of the skin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865067

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  EGFR expression in advanced head and neck cutaneous squamous cell carcinoma.

Authors:  Larissa Sweeny; Nichole R Dean; J Scott Magnuson; William R Carroll; Emily E Helman; Stephen O Hyde; Renee L Desmond; Eben L Rosenthal
Journal:  Head Neck       Date:  2011-07-07       Impact factor: 3.147

3.  Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Authors:  Kathryn A Gold; Merrill S Kies; William N William; Faye M Johnson; J Jack Lee; Bonnie S Glisson
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

Review 4.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.

Authors:  Vivian T Yin; Helen Merritt; Bita Esmaeli
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

5.  Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.

Authors:  Lee D Cranmer; Candace Engelhardt; Sherif S Morgan
Journal:  Oncologist       Date:  2010-12-08

6.  Targeted deletion of RasGRP1 impairs skin tumorigenesis.

Authors:  Amrish Sharma; Lauren L Fonseca; Cynthia Rajani; Jodi K Yanagida; Yuka Endo; J Mark Cline; James C Stone; Junfang Ji; Joe W Ramos; Patricia S Lorenzo
Journal:  Carcinogenesis       Date:  2014-01-24       Impact factor: 4.944

Review 7.  Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.

Authors:  Vivian T Yin; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Mar-Apr       Impact factor: 1.746

8.  Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Authors:  Justin G Madson; David T Lynch; Jessica Svoboda; Rebecca Ophardt; Jodi Yanagida; Sumanth K Putta; Andrew Bowles; Carol S Trempus; Raymond W Tennant; Laura A Hansen
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

9.  Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.

Authors:  Katie Ridd; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

10.  Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.

Authors:  William N William; Lei Feng; Renata Ferrarotto; Lawrence Ginsberg; Merrill Kies; Scott Lippman; Bonnie Glisson; Edward S Kim
Journal:  J Am Acad Dermatol       Date:  2017-09-28       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.